Balveen Kaur PhD


​ 

Balveen Kaur PhD
ProfessorCollege of Medicinekaur.11@osu.edu
385D Wiseman Hall 400 W 12th Avenue Columbus Ohio 43210
Phone:614-292-3984Fax: 614-688-4882
  • Viral Oncology

Current Publications

  • Baiocchi RAGenetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Onishi M, Kurozumi K, Ichikawa T, Michiue H, Fujii K, Ishida J, Shimazu Y, Chiocca EA, Kaur B, Date IGene expression profiling of the anti-glioma effect of Cilengitide.Springerplus 2 160 12/1/2013
  • Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, Chiocca EADNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.Clin Cancer Res 19 5952-9 11/1/2013
  • Racoma IO, Meisen WH, Wang QE, Kaur B, Wani AAThymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.PLoS One 8(9) e72882 9/9/2013
  • Stephenson JR, Paavola KJ, Schaefer SA, Kaur B, Van Meir EG, Hall RABrain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.J Biol Chem 288(31) 22248-56 8/2/2013
  • Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date IThe integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.Cancer Gene Ther 20(8) 437-44 8/1/2013
  • Price RL, Song J, Bingmer K, Kim TH, Yi JY, Nowicki MO, Mo X, Hollon T, Murnan E, Alvarez-Breckenridge C, Fernandez S, Kaur B, Rivera A, Oglesbee M, Cook C, Chiocca EA, Kwon CHCytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations.Cancer Res 73(11) 3441-50 6/1/2013
  • Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TPVEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.Mol Ther 21(5) 1014-23 5/1/2013
  • Meisen WH, Kaur BHow can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?Expert Rev Neurother 13(4) 341-3 4/1/2013
  • Onishi M, Ichikawa T, Kurozumi K, Fujii K, Yoshida K, Inoue S, Michiue H, Chiocca EA, Kaur B, Date IBimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.Neuropathology 33(2) 162-74 4/1/2013
  • Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JCEffective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.Mol Ther 21(3) 561-9 3/1/2013
  • Kaur B, Balgir PP, Mittu B, Kumar B, Garg NBiomedical applications of fermenticin HV6b isolated from Lactobacillus fermentum HV6b MTCC10770.Biomed Res Int 2013 168438 1/1/2013
  • Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EASTAT3 activation promotes oncolytic HSV1 replication in glioma cells.PLoS One 8(8) e71932 1/1/2013
  • Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, Wei M, Wang Y, He S, Hardcastle J, Fernandez SA, Kaur B, Lawler SE, Vivier E, Mandelboim O, Moretta A, Caligiuri MA, Chiocca EANK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Nat Med 18(12) 1827-34 12/1/2012
  • Gatson N, Chiocca EA, Kaur BAnti-angiogenic gene therapy in the treatment of malignant gliomas.Neurosci Lett 527(2) 62-70 10/11/2012
  • Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge C, Yu JG, Powell K, Mazar AP, Teknos TN, Old M, Glorioso JC, Chiocca EA, Kaur BCopper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.Clin Cancer Res 18(18) 4931-41 9/15/2012
  • Kaur B, Chiocca EA, Cripe TPOncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.Curr Pharm Biotechnol 13(9) 1842-51 7/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu